The uveitis treatment market is expected to witness a CAGR of around 6% during the forecast period. Uveitis is a form of eye inflammation that affects the middle layer of tissue in the eye wall (uvea). Possible causes of uveitis are infection, injury, an autoimmune or inflammatory disease, eye redness or pain, light sensitivity, blurred vision, floating spots in the patient’s field of vision, and decreased vision are some main factors for uveitis, and it can be serious, leading to permanent vision loss to the patient. Early diagnosis and treatment are important to prevent complications. Furthermore, the treatment provided by doctors is surgical procedures or some general medications according to the disease such as corticosteroids, immunosuppressants, monoclonal antibodies, cycloplegic agents, and drugs are the major factors for the growth of the uveitis treatment market. For instance, according to an article published by the Ocular Immunology and Uveitis Foundation in April 2022, uveitis afflicts 109,000 people in the U.S. and 43,000 new cases are diagnosed.
Download Free Sample of this Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=22860
According to UnivDatos Market Insights (UMI)’ research report “Uveitis Treatment Market”, is expected to witness a CAGR growth of around 6% during the forecast period 2021-2027F. This can be mainly attributed to an increase in government funding coupled with the development of novel drugs and treatments.
Based on drug class, the uveitis treatment market is segmented into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. The anti-inflammatory category is anticipated to witness a significant growth rate during the forecast period. The growth of this drug category is mainly due to the increasing cases of non-infectious eye diseases such as eye redness or pain, light sensitivity, blurred vision, etc. Further, major players in the market are increasing their focus on developing and launching new drugs for the treatment of uveitis. For instance, in March 2022, Bausch + Lomb and Clearside Biomedical launched “xipere” (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with anterior, intermediate, posterior, or pan uveitis in the U.S.
Download Free Sample of this Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=22860
Based on diseases, the uveitis treatment market is segmented into anterior uveitis, posterior uveitis, intermediate uveitis, and pan uveitis. The anterior uveitis category is anticipated to witness a significant growth rate during the forecast period. The growth of this category is mainly due to the high risk for people with untreated anterior uveitis leading to loss of vision as well as the development of cataract, glaucoma, or retinal edema coupled with the growing geriatric population. For instance, according to World Health Organization (WHO), around 253 million people across the globe live with vision impairment; of which, about 36 million are blind and 217 million suffer from moderate or severe vision impairment.
Based on distribution channel, the uveitis treatment market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. In 2020, the hospital pharmacies category is anticipated to witness a significant growth rate during the forecast period. Moreover, treatment of infectious or non-infectious eye diseases, such as cataracts, band keratopathy, cystoid macular edema, and autoimmune & inflammatory illnesses are performed in hospitals. For instance, according to the United Nations, the 60+ aged population was 962 million in 2017 and the number of the elderly population is expected to double again by 2050 and reach nearly 2.1 billion worldwide.
For more informative information, please visit us – https://univdatos.com/report/uveitis-treatment-market/
North America to witness extensive growth
For a better understanding of the market, the report provides a detailed analysis of major regions and countries including North America (U.S., Canada, Rest of America); Europe (Germany, U.K., France, Spain, Italy, Rest of Europe); Asia-Pacific (China, India, Japan, Rest of Asia-Pacific) and Rest of World. In 2020, North America accounted for a significant market share. This is mainly due to the increasing patient pool in the hospitals, rising cases of cystoid macular edema, and autoimmune & inflammatory illnesses. Furthermore, with high consumer spending on healthcare coupled with supportive reimbursement policies and advanced healthcare infrastructure, the region’s market is to witness significant during the forecast period.
According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the uveitis treatment market are AbbVie Inc., Alimera Sciences Inc., Allergan Plc., Amgen Inc., Bausch Health Companies Inc., Clearside Biomedical Inc., EyePoint Pharmaceuticals Inc., Mylan N.V., Novartis AG, and Santen Pharmaceutical Co. Ltd.
“Uveitis Treatment Market” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for the market players. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitors’ capabilities on different parameters. This will help companies in the formulation of go-to-market strategies and identifying the blue ocean for its offerings.
For more informative information, please visit us – https://univdatos.com/report/uveitis-treatment-market/
Market Segmentation:
1. By Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy & Targeted Therapies, Others)
2. By Diseases Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Pan uveitis)
3. By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online pharmacies)
4. By Company (AbbVie Inc., Alimera Sciences Inc., Allergan Plc., Amgen Inc., Bausch Health Companies Inc., Clearside Biomedical Inc., EyePoint Pharmaceuticals Inc., Mylan N.V., Novartis AG, and Santen Pharmaceutical Co. Ltd)
Key questions answered in the study:
1. What are the current and future trends of the uveitis treatment market?
2. How the industry has been evolving in terms of technology and application?
3. How the competition has been shaping across the countries followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the uveitis treatment market?
5. What is the customer orientation, purchase behavior, and expectations from the uveitis treatment market suppliers across various region and countries?
Table of Content –
1 MARKET INTRODUCTION
2 RESEARCH METHODOLOGY OR ASSUMPTION
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 UVEITIS TREATMENT MARKET COVID-19 IMPACT
6 UVEITIS TREATMENT MARKET REVENUE, 2019-2027F
7 MARKET INSIGHTS BY DRUG CLASS
8 MARKET INSIGHTS BY DISEASE TYPE
9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL
10 MARKET INSIGHTS BY REGION
11 UVEITIS TREATMENT MARKET DYNAMICS
12 UVEITIS TREATMENT MARKET OPPORTUNITIES
13 UVEITIS TREATMENT MARKET TRENDS
14 LEGAL & REGULATORY FRAMEWORK
15 DEMAND AND SUPPLY SIDE ANALYSIS
16 VALUE CHAIN ANALYSIS
17 COMPETITIVE SCENARIO
18 COMPANY PROFILED
19 DISCLAIMER
Browse Other Related Research Reports from UnivDatos Market Insights
· Patient Self-Service Kiosk Market to Reach US$ 1,637.5 Million by 2026 Globally | CAGR: 16.2%|
· Precision Medicine Market to Reach US$ 105.6 Billion by 2026, Globally |CAGR: 9.9%|
· Body Temperature Scanner Device Market to Exceed US$ 1 Billion by 2026, Globally |CAGR: 8.8%|
· Ophthalmic Devices Market to Reach US$ 46.3 Billion by 2026, Globally |CAGR: 5.2%|
Comments